SARS-CoV-2, HIV, and Mycobacterium tuberculosis triple co-infection.

Tuberculosis (TB)-related death has increased for the first time in a decade due to the coronavirus disease 2019 (COVID-19), globally. People living with HIV (PLWHIV) might be at a higher risk of developing COVID-19-related complications. Herein, we describe the first case of a patient surviving from SARS-CoV-2-TB-HIV triple co-infection in Cameroon. A 36-year-old Cameroonian woman presented at the emergency unit of the Jamot Hospital, Yaoundé with symptoms of anorexia, productive cough, weight loss, and fever. The SARS-CoV-2 rapid antigen test on nasopharyngeal sample was positive. Chest X-ray showed bilateral parenchymal and tracheal calcifications most consistent with prior pulmonary histoplasmosis, varicella, or TB. She was tested HIV positive, and the sputum sample tested positive for TB on auramine staining. TB therapy (rifampicin, isoniazid, pyrazinamide, and ethambutol) and COVID-19 treatment were initiated, and the symptoms improved after 2 weeks of treatment. The SARS-CoV-2 rapid antigen and real-time polymerase chain reaction tests were negative after 2 weeks. She was discharged home on antiretroviral therapy and TB therapy. Coinfection with both TB, HIV, and SARS-CoV-2 may be common in Cameroon but not reported. The similar clinical features of COVID-19 and TB usually lead to misdiagnosis. Early diagnosis and initiation of appropriate treatment improve outcome.
Competing Interests: None.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)